公开(公告)号：US20230095302A1

公开(公告)日：2023-03-30

申请号：US17935483

申请日：2022-09-26

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Bonnie DUMAIS ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  A61M5/142

Abstract: Disclosed are techniques and devices that are operable to receive one or a number of generalized parameters of an automated insulin delivery algorithm. An input of at least one generalized parameter corresponding to a user may be used to set one or more of the number of specific parameters of the automated insulin delivery algorithm based on the inputted at least one generalized parameter. Physiological condition data related to the user may be collected. The automated insulin delivery algorithm may determine a dosage of insulin to be delivered based on the collected physiological condition. Signals may be output to cause a liquid drug to be delivered to the user based on an output of the automated insulin delivery algorithm related to the determined dosage of insulin.

公开(公告)号：US20230067014A1

公开(公告)日：2023-03-02

申请号：US17821989

申请日：2022-08-24

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  John D'ARCO ,  David NAZZARO ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/315 ,  A61M5/20

Abstract: The exemplary embodiments may account for a change in potency of a medicament and adjust the dosage of medicament delivered to a user via a medicament delivery device to compensate for the change in potency. The medicament delivery device may determine the amount of change in the potency in the medicament and may make the adjustment in dosage of the medicament delivered to the user automatically without user input. The net result in that the dosage of medicament delivered to the user is better matched to the user's true need for the medicament.

公开(公告)号：US20230062884A1

公开(公告)日：2023-03-02

申请号：US17821994

申请日：2022-08-24

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  M. Thomas ANDERSEN

IPC: A61M5/315 ,  A61M5/20

Abstract: Disclosed are processes and techniques for a drug delivery system to maintain optimal drug delivery for a patient according to a treatment plan. The disclosed techniques enable a drug delivery system to delivery adjusted drug dosages and/or drug delivery cost function aggressiveness factors modified based on clusters or patterns of patient drug dosages and/or response event probabilities. For example, a controller for operating a drug delivery device may operate to determine a plurality of dosage clusters for a patient based on drug dosage patient information, determine an adjustment profile for each of the dosage clusters, determine a current cluster for a dosage cycle, determine an adjusted dosage for the dosage cycle by applying the adjustment profile to a default dosage, and provide a signal to the drug delivery device to deliver the adjusted dosage to the patient for the dosage cycle. Other embodiments are described.

公开(公告)号：US20230001088A1

公开(公告)日：2023-01-05

申请号：US17848673

申请日：2022-06-24

Applicant: INSULET CORPORATION

Inventor： Ashutosh ZADE ,  Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142

Abstract: The switchover between an expiring on-body medicament delivery device and a replacement on-body medicament is made to eliminate or significantly decrease the time where an on-body medicament delivery device is operational to deliver medicament to a user. The replacement on-body medicament device is attached to the user and prepped for operation while the expiring on-body medicament delivery device is still operational. The switchover between on-body sensors also may be improved. Methods for calibrating a replacement on-body sensor while the expiring on-body sensor is still operative are provided. The calibrating may be performed quickly so that there is no gap in operation between expiration of the expiring on-body sensor and full operation of the replacement on-body sensor.

公开(公告)号：US20220395637A1

公开(公告)日：2022-12-15

申请号：US17839645

申请日：2022-06-14

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142

Abstract: The disclosed embodiments are directed to methods for determining, based on input from a manual insulin delivery device, for example, an insulin pen, a proper bolus dosing to be delivered by an AID system, to assess the sufficiency of the user-administered basal dose of long-acting insulin and to recommend any changes to the long-acting delivery following a daily analysis of the user's blood glucose readings.

公开(公告)号：US20220392603A1

公开(公告)日：2022-12-08

申请号：US17834332

申请日：2022-06-07

Applicant: INSULET CORPORATION

Inventor： Ashutosh ZADE ,  Joon Bok LEE ,  Yibin ZHENG

IPC: G16H20/30 ,  A61B5/00 ,  A61M5/172 ,  G16H20/17

Abstract: Described are techniques, processes, devices, computer-readable media that enable provision of an indication of whether it is safe for a person with diabetes to participate in exercise while using a wearable drug delivery system. A processor may receive or obtain physiological data related to a condition of a wearer of the wearable drug delivery system and by evaluating an exercise model that uses inputs related to the physiological data to make the determination of whether it is safe to exercise and output an exercise safety signal. Modifications to the wearer's medication treatment plan and other actions may be based on an outputted exercise safety signal.

公开(公告)号：US20220168505A1

公开(公告)日：2022-06-02

申请号：US17534129

申请日：2021-11-23

Applicant: Insulet Corporation

Inventor： Mengdi LI ,  Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172

Abstract: Processes and devices are disclosed that are configured to respond to changes in a user's blood glucose caused by ingestion of a meal. Ingestion of the meal may be announced by a user input or by a meal detection algorithm that requires no user input. The responsive device and processes determine a carbohydrate-compensation insulin dosage based on a user's blood glucose history, external data related to the user's meal history, or based on a user's response to previous carbohydrate-compensation insulin dosages. In addition, a correction insulin dosage may be calculated to cover any gap between a starting blood glucose and a target blood glucose. A user's response to a sum of the carbohydrate-compensation insulin dosage and the correction insulin dosage may be delivered. Based on the user's response, the disclosed examples may determine modifications to the carbohydrate-compensation insulin dosage, the correction insulin dosage, or both.

公开(公告)号：US20220088303A1

公开(公告)日：2022-03-24

申请号：US17027191

申请日：2020-09-21

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Steven CARDINALI ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/168

Abstract: Methods and apparatuses for performing an insulin infusion process are described. For example, an apparatus may include at least one memory and logic coupled to the at least one memory. The logic may operate to determine a basal parameter for a patient based on a type 2 diabetes (T2D) multiple daily injection (MDI) information of the patient, the basal parameter indicating a basal infusion rate, determine an additional insulin (Iadd) value based on a mean blood glucose difference (BGdiff) information associated with the patient, determine an insulin volume to infuse into the patient based on the basal parameter and Iadd, and administer the insulin volume to the patient. Other embodiments are described.

公开(公告)号：US20220031944A1

公开(公告)日：2022-02-03

申请号：US16945246

申请日：2020-07-31

Applicant: Insulet Corporation

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142 ,  A61K38/28 ,  G16H20/17 ,  G16H40/67 ,  G05B15/02 ,  G05D7/06

Abstract: Disclosed are techniques to establish a modified pump rate that mitigates the effects of a pump occlusion and enables a recommended dosage of insulin to be output by a pump mechanism over the course of a control cycle. In an example, the pump rate may be reduced by adding a calculated time interval between application of actuation commands to extend the amount of time over which insulin may be output by the pump mechanism.

公开(公告)号：US20210308377A1

公开(公告)日：2021-10-07

申请号：US16840483

申请日：2020-04-06

Applicant: INSULET CORPORATION

Inventor： Mengdi LI ,  Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  G16H40/67 ,  G16H10/60 ,  G16H20/17 ,  G16H50/20 ,  G16H50/70 ,  G16H10/40 ,  G16H50/30 ,  G16H50/50

Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.